Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals plc (JAZZ) is a Healthcare stock tracked by StreetAlpha. JAZZ reports earnings on Mon, Nov 2, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 14 firms (14 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in JAZZ, 100% of them bullish and 0% bearish. In the past 30 days there were 3 dark pool prints.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 21 | Morgan Stanley | Target lowered | Buy | — |
| Oct 8 | RBC Capital | Maintained | Buy | — |
| Oct 7 | Truist Securities | Target raised | Buy | — |
| Sep 30 | Citigroup | Initiated | Buy | — |
| Sep 24 | Goldman Sachs | Reinstated | Buy | — |
Whale Options Flow
90DDark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether JAZZ is in one of them and how their past JAZZ trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered JAZZ in an article yet. Here's the latest on the wider market.
JAZZ Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Bryan BedfordExecutive branch | Sell | $50K – $100K | Sep 10, 2025 | Dec 19, 2025 | 100 d |
| Dan GoldmanD · NY | Sell | $15K – $50K | Jul 12, 2023 | Aug 13, 2023 | 32 d |
| Ro KhannaD · CA | Sell | $1K – $15K | May 19, 2023 | Jun 12, 2023 | 24 d |
| Dan GoldmanD · NY | Buy | $15K – $50K | Mar 6, 2023 | Apr 17, 2023 | 42 d |
| Ro KhannaD · CA | Buy | $1K – $15K | Mar 14, 2023 | Apr 7, 2023 | 24 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.





